China's new supply chain rules threaten Western pharma as Beijing tightens control over biotech imports

China has rapidly expanded its role in drug development, moving from less than 8% of global clinical trials in 2010 to overtaking the United States in trial volume by 2020, with more than 5,000 trials registered in 2024. Most of this growth comes from domestic Chinese companies rather than multinational R&D relocations.

On April 7, China’s State Council issued Decree No. 834, the Regulations on Industrial and Supply Chain Security, which took effect immediately. The 18‑article decree grants Beijing broad authority to investigate and sanction foreign firms whose commercial actions are judged to threaten China’s industrial chain security.

The new rules pose significant challenges for Western biopharma firms that rely on China for manufacturing or clinical research. Companies may face sanctions, supply interruptions, or forced adjustments to their business models as they navigate the heightened regulatory environment.

The decree is part of China’s 15th five‑year plan, which explicitly prioritizes biotechnology and pharmaceuticals, underscoring a strategic shift toward self‑sufficiency and global competitiveness in the sector.